Getmedicin.org

Actavis





Allergan Escapes Valeant39s Pursuit, Agreeing to Be Bought by Actavis

12/10/2014
04:39 | Author: Ryan Brooks

Where can you buy promethazine with codeine over the counter
Allergan Escapes Valeant39s Pursuit, Agreeing to Be Bought by Actavis

Allergan agreed on Monday to be acquired for $66 billion by Actavis in a deal worth $219 a share in cash and stock. The deal would be the.

Comments (0)



ACT Summary for Actavis plc Ordinary Shares- Yahoo! Finance

12/10/2014
06:38 | Author: Alex Watson

Actavis
ACT Summary for Actavis plc Ordinary Shares- Yahoo! Finance

View the basic ACT stock chart on Yahoo! Finance. Change the date range, chart type and compare Actavis plc Ordinary Shares against other companies.

Add ACT Headlines to My Yahoo!

Wed, Dec 10, 2014, 1:20AM EST - U.S. Markets open in 8 hrs 10 mins.

Fundamental company data provided by Capital IQ. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data, daily updates, fund summary, fund performance, dividend data and Morningstar Index data provided by Morningstar, Inc. Orderbook quotes are provided by BATS Exchange. US Financials data provided by Edgar Online and all other Financials provided by Capital IQ. International historical chart data, daily updates, fundAnalyst estimates data provided by Thomson Financial Network. All data povided by Thomson Financial Network is based solely upon research information provided by third party analysts. Yahoo! has not reviewed, and in no way endorses the validity of such data. Yahoo! and ThomsonFN shall not be liable for any actions taken in reliance thereon.

Quotes are real-time for NASDAQ, NYSE, and NYSE MKT. See also delay times for other exchanges. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.

* (Strong Buy) 1.0 - 5.0 (Sell).

Add ACT Headlines to My Yahoo!

Comments (0)

And The Winners Are Actavis, Allergan And Ackman - Forbes

12/10/2014
08:57 | Author: Tyler James

Actavis
And The Winners Are Actavis, Allergan And Ackman - Forbes

With White Knight Actavis standing in its corner, Allergan was able to outmaneuver Valeant Pharmaceuticals and Bill Ackman's hedge fund.

Forbes writers have the ability to call out member comments they find particularly interesting. Called-out comments are highlighted across the Forbes network. You'll be notified if your comment is called out.

On average Mr. Ackman purchased his position for $129.28 per share before April 2014. Since then, the share price has increased 70%, bringing the total value of his position to over $6.3BN. Mr. Ackman and his hedge fund stand to clear $2.6BN in profit after the acquisition of Allergan by Actavis.

Comments (3)Read more

Suvretta39s Cowen says Actavis stock could nearly double Reuters

12/10/2014
12:04 | Author: Hannah Ramirez

Actavis
Suvretta39s Cowen says Actavis stock could nearly double Reuters

N) Chief Executive David Pyott made the right call in selling to rival Actavis Plc (ACT.N), whose stock price could nearly double in the next two.

Pyott "did sell to the right company and we thought this was the right outcome," hedge fund manager Aaron Cowen said at the Reuters Global Investment Outlook Summit about the year's biggest pharmaceutical deal.

Botox-maker Allergan on Monday agreed to sell itself to Actavis for $66 billion, in a deal that came in far above the offer that rival Valeant Pharmaceuticals ( VRX.TO ) and hedge fund manager William Ackman had been making since the end of April.

NEW YORK Wed Nov 19, 2014 4:23pm EST.

NYSE and AMEX quotes delayed by at least 20 minutes.

Comments (4)Read more

Allergan agrees to 66 billion Actavis offer Valeant walks Reuters

12/10/2014
02:55 | Author: Sarah Gray

Actavis
Allergan agrees to 66 billion Actavis offer Valeant walks Reuters

(Reuters) - Botox maker Allergan Inc on Monday accepted a $66 billion takeover bid from Actavis Plc, ending a seven-month hostile pursuit by.

(Reporting by Caroline Humer; Additional reporting by Rod Nickel in Winnipeg, Manitoba and Ransdell Pierson in New York; Editing by Bernadette Baum and Lisa Von Ahn) Back to top.

Valeant, meanwhile, may find new acquisition targets more willing to push back on its overtures, some of its investors said. FRIENDLY APPROACH.

(Reuters) - Botox maker Allergan Inc on Monday accepted a $66 billion takeover bid from Actavis Plc, ending a seven-month hostile pursuit by activist investor William Ackman and Valeant Pharmaceuticals International Inc.

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on, video, mobile, and interactive evision platforms.

Comments (5)Read more